Dechra Pharmaceuticals PLC
DPHAYOTCHealthcare
$98.00
+$1.90(+1.98%)
Market Cap$5.6B
P/E Ratio—
52W High$98.0
52W Low$61.61
Dechra Pharmaceuticals PLC (DPHAY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DPHAY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-06 | 2022-06 | 2021-06 | 2020-06 | 2019-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.76B | $0.68B | $0.61B | $0.52B | $0.48B |
| Cost of Revenue | $0.34B | $0.30B | $0.26B | $0.22B | $0.21B |
| Gross Profit | $0.43B | $0.38B | $0.35B | $0.29B | $0.27B |
| Gross Margin %(computed) | 55.98% | 56.44% | 56.89% | 56.61% | 56.68% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.04B | $0.03B | $0.03B | $0.03B |
| G&A Expenses | $0.36B | $0.18B | $0.15B | $0.13B | $0.13B |
| Total Operating Expenses | $0.42B | $0.21B | $0.26B | $0.23B | $0.23B |
| Operating Income | $0.01B | $0.10B | $0.08B | $0.05B | $0.04B |
| Operating Margin %(computed) | 0.83% | 14.01% | 13.82% | 10.13% | 8.09% |
| Interest Income | $0.00B | $0.00B | $0.01B | $0.00B | $0.01B |
| Interest Expense | $0.04B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.04B) | $0.08B | $0.07B | $0.04B | $0.03B |
| Income Tax Expense | ($0.01B) | $0.02B | $0.02B | $0.01B | ($0.00B) |
| Net Income | ($0.03B) | $0.06B | $0.06B | $0.03B | $0.03B |
| Net Margin %(computed) | -3.66% | 8.54% | 9.13% | 6.58% | 6.41% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.24 | $0.54 | $0.51 | $0.33 | $0.30 |
| Wtd Avg Shares | 0.11B | 0.11B | 0.11B | 0.10B | 0.10B |
| EBITDA | $0.09B | $0.18B | $0.16B | $0.13B | $0.12B |
| EBITDA Margin %(computed) | 11.39% | 26.24% | 26.64% | 25.43% | 25.45% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · GBP · B
Explore more Dechra Pharmaceuticals PLC data
About Dechra Pharmaceuticals PLC (DPHAY) Income Statement
Dechra Pharmaceuticals PLC (DPHAY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, DPHAY reported revenue of $0.76B, gross profit of $0.43B (gross margin 55.98%), and net income of ($0.03B) — a net profit margin of -3.66%.
Frequently asked questions
DPHAY · 4 questionsDechra Pharmaceuticals PLC (DPHAY) reported revenue of $0.76B for 2023, up 11.7% year-over-year.
DPHAY revenueDPHAY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08